Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension

Christina Lindén, Eva Nuija, Albert Alm

Abstract

Aims—To evaluate whether long term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment.

Methods—Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 µg/ml once daily for 6–12 months. In 26 patients IOP was followed for 14 days after withdrawal of treatment. Aqueous flare was measured with a laser flare meter during 6–12 months' treatment in 16 patients.

Results—On the last day of treatment IOP was 6.9 mm Hg (95% CI 5.3–8.5) lower than before treatment. It increased slowly during the follow up period but was still 1.3 mm Hg (95% CI 0.2–2.5) lower than pretreatment IOP 14 days after cessation of treatment. No change in aqueous flare was seen throughout the study.

Conclusion—Latanoprost has no clinically significant effect on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks, indicating that latanoprost is safe for long term treatment.

(*Br J Ophthalmol* 1997;81:370–372)

Latanoprost (13,14-dihydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropyl ester), is a prostaglandin F_{2α} (PGF_{2α}) analogue currently undergoing evaluation in long term clinical trials. The substance effectively reduces IOP in humans.^{1–4} Its main mechanism of action seems to be an increase in uveoscleral outflow of aqueous humour^{2–5,6} but the exact mechanism is not known. Morphological changes have been found in the ciliary muscle in monkeys after topical application of PGF_{2α}. These include widening of intramuscular spaces⁷ and loss of collagen type I and III fibrils in the connective tissue between the muscle bundles.⁸ The investigators suggest that structural changes of the ciliary muscle can contribute to the pressure reducing effects of prostaglandins. They found that significant morphological changes are probably limited to the ciliary muscle and they found no evidence of an effect on the blood-aqueous barrier (BAB). Such an effect has been observed in rabbits^{9–10} while the BAB in monkeys seems to be much more resistant.^{11–12} No signs of BAB breakdown have

been noted in human eyes during short term studies.^{13–15}

The possibility of morphological changes occurring in the human ciliary muscle is particularly important since the drug is intended for long term treatment. Irreversible changes in the ciliary muscle could result in a persisting ocular hypotensive effect. For this reason we observed the time for restoration of IOP to pretreatment levels after withdrawal of latanoprost. IOP was followed for 14 days after discontinuation of treatment in a group of 26 patients treated with latanoprost for 6–12 months within the framework of a phase III clinical trial (6 month report⁴).

Additionally, we addressed the question of whether long term treatment with latanoprost has a deleterious effect on the BAB. Thus, 16 patients treated in one of the centres were followed with a laser flare meter.

Material and methods

STUDY OF IOP RESTORATION

Patient selection

After completion of a Scandinavian 6 month, multicentre, double masked clinical trial on latanoprost versus timolol,⁴ or its open labelled extension, patients from two centres (Umeå and Uppsala) were invited to participate in a follow up study. To be eligible for the present study at least one eye had to be topically treated with latanoprost 50 µg/ml once daily for a minimum of 6 months. Fifteen of the 26 patients accepting the study procedure had been receiving latanoprost for 1 year.

Examination schedule and procedures

All patients were examined on the last day of latanoprost treatment (day 0) and 1, 3, 7, and 14 days later. The time for the last eyedrop was noted and the patient was allowed to choose visiting hours, either 8 am or noon. The same time schedule had to be maintained throughout the study. Pretreatment values were obtained from the corresponding time points at the baseline day of the long term study—that is, before any treatment had been initiated.

Within each centre the same calibrated Goldmann applanation tonometer was utilised for the IOP determinations and all tonometry on a given patient was made by the same person. The median of three readings in each eye treated with latanoprost was used for calculations. If both eyes were treated the mean IOP of the two eyes was used in the analyses. *p* Values less than 0.05 with Student's paired *t* test were considered statistically significant.

Department of
Ophthalmology, Umeå
University, S-901 85
Umeå, Sweden
C Lindén

Department of
Ophthalmology,
Uppsala University,
S-751 85 Uppsala,
Sweden
E Nuija
A Alm

Correspondence to:
Dr C Lindén, Department of
Ophthalmology, Umeå
University, S-901 85 Umeå,
Sweden.

Accepted for publication
11 December 1996

Figure 1 Mean difference (pretreatment IOP - IOP during follow up) versus time after cessation of latanoprost treatment. Error bars denote 95% confidence interval. ($n = 26$.)

STUDY OF FLARE

Patient selection

All patients from one centre (Uppsala), eligible for the multicentre trial, were offered flare measurements. Eighteen of 20 patients accepted these extra measurements, but two patients were excluded from the analysis because they had had less than 6 months' follow up.

Examination schedule and procedures

Anterior chamber flare was determined by a laser flare meter (FM-500, Kowa, Japan) and flare intensity was given as photon counts per millisecond. Measurements were performed before entering the study and after 3, 6, and 12 months on latanoprost. At 3 and 12 months only 13 and 10 patients, respectively, were assessed. This was because of the study design and length of follow up. In two patients the baseline measurement was made after 2 weeks' treatment. At each time point 10 determinations were performed and the mean was used for calculations. If both eyes were treated the average of the two eyes was used. p Values less than 0.05 with Student's t test were considered statistically significant.

Results

STUDY OF IOP RESTORATION

Twenty six white patients, 16 women and 10 men, with primary open angle glaucoma, capsular glaucoma, or ocular hypertension entered and completed the study per protocol. Their median age was 68 years (range 61–84). Eight patients were treated bilaterally and 18 in one eye only.

According to the time for the last eyedrop (8 am or 8 pm) and the time chosen for tonometry readings, measurements were obtained 4–24 hours and 24–40 hours after the last eyedrop on day 0 and on day 1, respectively. Figure 1 shows the mean difference (pretreatment IOP - IOP during follow up) in treated eyes from day 0 to day 14. The IOP was significantly lower than pretreatment IOP at all times, but the difference gradually declined from 7.2 mm Hg on day 1 ($p < 0.001$) to 1.3 mm Hg on day 14 ($p = 0.02$).

STUDY OF FLARE

Flare was followed in 16 patients throughout 6–12 months of latanoprost treatment. There were 10 women and six men, aged 60–77

Figure 2 Mean flare intensity versus time. Filled circles represent treated eyes, open circles untreated eyes. Error bars denote half the 95% confidence interval. ($n = 10$ –16.)

(median 72) years. Two patients were treated bilaterally, the remainder received latanoprost in one eye.

Flare intensity in treated and untreated eyes is presented in Figure 2. No statistically significant differences were seen throughout the study, neither was there a marked increase in flare in any single individual. The maximal flare values before treatment were 13.00 photon counts/ms in treated eyes and 9.43 in untreated eyes. The corresponding figures during treatment were 10.48 and 10.25.

Discussion

The IOP reduction after 6–12 months of treatment declined slowly but some reduction remained for 14 days after discontinuation of treatment. A correspondingly slow restoration of the IOP is seen after withdrawal of timolol.¹⁶ This is thought to be due to the binding of timolol to melanin, giving a slow release effect.¹⁷ Latanoprost, on the other hand, is not bound to melanin and it cannot be found in aqueous humour 24 hours after topical administration (unpublished observations). Latanoprost is the biologically active epimer of PhXA34. In previous studies where PhXA34 was applied for 1–2 weeks a significant retained effect on IOP was observed 2¹⁸ to 6¹³ days later. The results of the present study show that the IOP reduction is transient even after treatment for up to 12 months. Thus, the effect on IOP of possible morphological changes in the ciliary muscle involved in the IOP reduction is reversible and will be restored to pretreatment levels within a few weeks after discontinuation of treatment. As latanoprost seems to be as effective as PGF_{2α} in terms of reducing IOP it may be reasonable to assume that the two drugs cause similar changes in the ciliary muscle morphology. In monkeys treatment with large doses of PGF_{2α} or its isopropyl ester for 4–8 days induces loss of extracellular material between, but not within, the ciliary muscle bundles.^{7,8} Collagen type I and III fibrils are lost and ciliary muscle fibres are thin or relaxed. Whether similar changes occur in human eyes is not known. As latanoprost is a much more specific prostaglandin F receptor (FP receptor) agonist than PGF_{2α}¹⁹ it is also possible that the effect on the ciliary muscle morphology differs. If the morphological changes are similar the slow restoration of IOP after long term treatment suggests a correspondingly slow

rebuilding of extracellular material, but morphological examinations of relevant tissue specimens are needed to clarify this issue.

Several short term studies with different techniques—for example, iris fluorescein angiography,²⁰ fluorophotometry,^{13 14 21} and laser flare meter measurements¹⁵ have failed to detect any significant effect of the BAB caused by topical treatment with PGF_{2α} and latanoprost. These results have been confirmed in the present investigation, where 16 patients treated with latanoprost once daily were followed with laser flare measurements for 6–12 months. There was no statistically significant difference between the means of the treated and the non-treated eyes at any time or between pre- and post-treatment measurements in treated eyes, nor did any treated eye show a larger change in flare values than could be seen in non-treated eyes. It may thus be concluded that latanoprost has no effect on the permeability of the BAB to proteins.

In conclusion, long term treatment with latanoprost has no clinically important effects on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks after discontinuation of treatment. The results indicate that latanoprost is safe for long term treatment with respect to the BAB and that the effect on IOP of possible morphological changes in the ciliary muscle are reversible.

- 1 Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, *et al.* Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. *Ophthalmology* 1993;100:1312–7.
- 2 Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F_{2α} analog, on aqueous humor dynamics in human eyes. *Ophthalmology* 1993;100:1297–304.
- 3 Alm A, Widengård I, Kjellgren D, Söderström M, Friström B, Heijl A, *et al.* Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. *Br J Ophthalmol* 1995;79:12–6.
- 4 Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. *Ophthalmology* 1995;102:1743–52.
- 5 Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F_{2α}-1-isopropylester in the cynomolgus monkey. *Exp Eye Res* 1989;48:707–16.
- 6 Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F_{2α}-induced ocular hypotension in monkeys. *Arch Ophthalmol* 1987;105:1112–6.
- 7 Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F_{2α}. *Exp Eye Res* 1988;47:761–9.
- 8 Tamm E, Rittig M, Lütjen-Drecoll E. Elektronenmikroskopische und immunhistochemische Untersuchungen zur augendrucksenkenden Wirkung von Prostaglandin F_{2α}. *Fortschr Ophthalmol* 1990;87:623–9.
- 9 Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. *Invest Ophthalmol Vis Sci* 1977;16:1125–34.
- 10 Lee P, Podos SM, Severin C. Effect of prostaglandin F_{2α} on aqueous humor dynamics of rabbit, cat and monkey. *Invest Ophthalmol Vis Sci* 1984;25:1087–93.
- 11 Camras CB, Bhuyan KC, Podos SM, Bhuyan DK, Master RWP. Multiple dosing of prostaglandin F_{2α} or epinephrine on cynomolgus monkey eyes. II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. *Invest Ophthalmol Vis Sci* 1987;28:921–6.
- 12 Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF_{2α} on aqueous humor dynamics in cynomolgus monkeys. *Curr Eye Res* 1987;6:1035–44.
- 13 Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. *Arch Ophthalmol* 1991;109:1564–8.
- 14 Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F_{2α} analogue, after topical application in normal and ocular hypertensive human eyes. *Arch Ophthalmol* 1993;111:1351–8.
- 15 Hotehama Y, Mishima HK. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F_{2α}-isopropyl ester analogues for glaucoma treatment. *Jpn J Ophthalmol* 1993;37:259–69.
- 16 Schlecht LP, Brubaker RF. The effects of withdrawal of timolol in chronically treated glaucoma patients. *Ophthalmology* 1988;95:1212–6.
- 17 Menon IA, Trope GE, Basu PK, Wakeham DC, Persad SD. Binding of timolol to iris-ciliary body and melanin: an in vitro model for assessing the kinetics and efficacy of long-acting antiglaucoma drugs. *J Ocul Pharmacol* 1989;5:313–24.
- 18 Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, *et al.* Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. *Arch Ophthalmol* 1992;110:1733–8.
- 19 Stjernschantz J, Selén G, Sjöquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl substituted PGF_{2α} analogue. In: Samuelsson B, ed. *Advances in prostaglandin, thromboxane, and leukotriene research*. New York: Raven Press, 1995:513–8.
- 20 Giuffrè G. The effects of prostaglandin F_{2α} in the human eye. *Graefes Arch Clin Exp Ophthalmol* 1985;222:139–41.
- 21 Villumsen J, Alm A. Prostaglandin F_{2α}-isopropylester eye drops: effects in normal human eyes. *Br J Ophthalmol* 1989;73:419–26.